These inhibitors (74–76) were effective for AML of both high- and low-risk groups, and most of them had lower IC50 in high-risk groups, suggesting that inhibition of the PI3K signaling pathway may provide a new potential approach for AML treatment. This evidence concerns the gene PIK3CA and acute myeloid leukemia.